Electrocardiographic Markers of Atrial Cardiomyopathy: Strengths and Limits of P‐Wave–Based Assessment
Mehmet Mustafa Yılmaz, Mücahit Aker, Macit Kalçık

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAtrial Fibrillation Management and Outcomes · Cardiovascular Function and Risk Factors · Cardiac Arrhythmias and Treatments
To the Editor,
We read with interest the article by Kazantzi et al. examining the association between established P‐wave parameters and left atrial hemodynamics in the context of atrial cardiomyopathy (ACM) (Kazantzi et al. 2026). The authors should be acknowledged for addressing a clinically relevant question using a prospective design and comprehensive echocardiographic assessment. Their conclusion that advanced interatrial block (IAB) is the most reliable electrocardiographic marker of impaired left atrial function is clearly presented and supported by internal consistency within the dataset.
Nevertheless, several methodological aspects warrant closer scrutiny. The study population is heterogeneous, comprising patients with prior atrial fibrillation, embolic stroke of undetermined source, and individuals without manifest cardiovascular disease. While this broad inclusion enhances external validity, it may dilute pathophysiologically specific associations between P‐wave indices and atrial remodeling. Current consensus documents emphasize that ACM represents a spectrum with variable electrical, structural, and mechanical manifestations, and pooling such diverse phenotypes may obscure parameter‐specific diagnostic performance (Goette et al. 2024).
A further concern relates to the operational definition of pathological P‐wave parameters. Thresholds derived from consensus recommendations are largely based on epidemiological associations rather than mechanistic validation against atrial tissue pathology or gold‐standard imaging. In particular, the dismissal of P‐wave terminal force in lead V1 as a hemodynamic marker may reflect cohort characteristics rather than a true lack of biological relevance, given its previously demonstrated association with atrial fibrosis and stroke risk in population‐based studies (Kamel et al. 2014).
Additionally, the reliance on cross‐sectional echocardiographic markers limits causal inference. Left atrial strain and PA‐TDI are sensitive indicators of atrial function, yet they remain load‐dependent and subject to inter‐vendor variability. Longitudinal assessment or correlation with advanced imaging modalities such as late gadolinium‐enhanced cardiac magnetic resonance imaging could have strengthened the argument that advanced IAB truly captures the substrate of atrial cardiomyopathy rather than representing an epiphenomenon of aging and comorbidity burden (Bisbal et al. 2020).
Finally, the clinical implications of prioritizing advanced IAB over other P‐wave parameters deserve cautious interpretation. While advanced IAB appears strongly associated with impaired atrial hemodynamics, its relatively low prevalence may limit utility as a screening tool. A multiparametric approach integrating electrocardiographic, echocardiographic, and biomarker data may better reflect the complex biology of ACM and align with contemporary views of atrial disease as a continuum rather than a binary entity (Kreimer and Gotzmann 2022).
Author Contributions
All of the authors contributed to planning, writing, and revision.
Funding
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Bisbal, F. , A. Baranchuk , E. Braunwald , A. Bayés de Luna , and A. Bayés‐Genís . 2020. “Atrial Failure as a Clinical Entity: JACC Review Topic of the Week.” Journal of the American College of Cardiology 75, no. 2: 222–232.31948652 10.1016/j.jacc.2019.11.013 · doi ↗ · pubmed ↗
- 2Goette, A. , D. Corradi , D. Dobrev , et al. 2024. “Atrial Cardiomyopathy Revisited‐Evolution of a Concept: A Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).” Europace 26, no. 9: euae 204.39077825 10.1093/europace/euae 204PMC 11431804 · doi ↗ · pubmed ↗
- 3Kamel, H. , E. Z. Soliman , S. R. Heckbert , et al. 2014. “P‐Wave Morphology and the Risk of Incident Ischemic Stroke in the Multi‐Ethnic Study of Atherosclerosis.” Stroke 45, no. 9: 2786–2788.25052322 10.1161/STROKEAHA.114.006364 PMC 4146624 · doi ↗ · pubmed ↗
- 4Kazantzi, M. , A. Mohr , R. Schneider , et al. 2026. “Association of P‐Wave Parameters With Left Atrial Hemodynamics in Atrial Cardiomyopathy.” Annals of Noninvasive Electrocardiology 31, no. 1: e 70145.41414789 10.1111/anec.70145 PMC 12715353 · doi ↗ · pubmed ↗
- 5Kreimer, F. , and M. Gotzmann . 2022. “Left Atrial Cardiomyopathy—A Challenging Diagnosis.” Frontiers in Cardiovascular Medicine 9: 942385.35845077 10.3389/fcvm.2022.942385 PMC 9280085 · doi ↗ · pubmed ↗
